Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.
Claudio Vernieri(IFOM), Giuseppe Curigliano(University of Milan), Francesco Pantano(Università Campus Bio-Medico), Angela Toss(University of Modena and Reggio Emilia), Alberto Zambelli, Monica Giordano(Ospedale Sant'Anna), Andrea Botticelli(Sapienza University of Rome), Paolo Vigneri(Humanitas University), Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Mario Giuliano(Regione Campania), Marianna Sirico(Istituti Ospitalieri di Cremona), Barbara Tagliaferri(Istituti Clinici Scientifici Maugeri), Maria Vittoria Dieci(Istituto Oncologico Veneto), Matteo Lambertini(Ospedale Policlinico San Martino), Rebecca Pedersini(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Leonardo Provenzano(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Saverio Cinieri(Ospedale A. Perrino), Gianpiero Rizzo(Policlinico San Matteo Fondazione), Marta Piras(Associazione Medici Diabetologi)
Cited by 1
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k